Pasar al contenido principal

FISIOLOGIA Y FISIOPATOLOGIA CARDIACA IN VIVO CON SONDAS DE CALCIO LUMINISCENTES EN PEZ CEBRA

BFU2015-69874-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario UNIVERSIDAD DE CASTILLA-LA MANCHA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dadun. Depósito Académico Digital de la Universidad de Navarra
Publicación Artículo científico (JournalArticle)

The p.E152K-STIM1 mutation deregulates Ca2+ signaling contributing to chronic pancreatitis

  • Burgos-Lozano, M. (Miguel)|||/items/1a21c8a8-c6ed-4d08-9270-6a8e82a35804
  • Philippe, R. (Reginald)|||/items/b130c236-8dba-4e7d-9168-95fbee81826d
  • Antigny, F. (Fabrice)|||/items/368cb14a-5400-4e4d-b2ef-7213bb212ac5
  • Buscaglia, P. (Paul)|||/items/a6d8fb3c-d083-4fe5-ae96-0bd499e033ac
  • Masson, E. (Emmanuelle)|||/items/871bdb22-263d-4d44-845c-ba3f14f2d8b3
  • Mukherjee, S. (Sreya)|||/items/3504dbc4-e46b-42eb-a980-bf4ca4f16c91
  • Dubar, P. (Pauline)|||/items/57004e14-f426-401d-acdd-2c7a17130b44
  • Le-Marechal, C. (Cédric)|||/items/d717fb19-1773-4f6d-a061-f0c2b5827a6d
  • Campeotto, F. (Florence)|||/items/d28734de-c658-4e49-8c81-1a26b00a4765
  • Lebonvallet, N. (Nicolas)|||/items/1c57b2ff-070e-4e70-a4d3-d1df5dab3396
  • Frieden, M. (Maud)|||/items/f6d9ea48-1928-43eb-a736-718a76a5e6e4
  • Llopis, J. (Juan)|||/items/17a5c539-5f9c-4e4d-a29c-322309a38576
  • Domingo, B. (Beatriz)|||/items/903a7461-0bb5-4cd7-8203-79e46014a533
  • Stathopulos, P.B. (Peter B.)|||/items/24751f65-2804-4e17-8cc5-9d24257b825e
  • Mitsuhiko, I. (Ikura)|||/items/659ff8df-1606-41a3-84c0-2ca69c43a87d
  • Brooks, W. (Wesley)|||/items/22c165f4-0452-4f22-abd5-2462b62b4a10
  • Guida, W. (Wayne)|||/items/ba4083ea-6f1e-4a83-b3f5-bc9291d3c4ab
  • Chen, J.M. (Jian-Min)|||/items/0993a44c-b666-4537-bd4f-e72614d397a3
  • Ferec, C. (Claude)|||/items/72ad72b7-0479-492e-8910-7d654366395d
  • Capiod, T. (Thierry)|||/items/07a2f629-74ae-46b8-b657-34a32d20be91
  • Mignen, O. (Oliver)|||/items/53b832b6-a720-47a5-9b7d-1f3c63f178a7
Since deregulation of intracellular Ca2+ can lead to intracellular trypsin activation, and stromal interaction molecule-1 (STIM1) protein is the main regulator of Ca2+ homeostasis in pancreatic acinar cells, we explored the Ca2+ signaling in 37 STIM1 variants found in three pancreatitis patient cohorts. Extensive functional analysis of one particular variant, p.E152K, identified in three patients, provided a plausible link between dysregulated Ca2+ signaling within pancreatic acinar cells and chronic pancreatitis susceptibility. Specifically, p.E152K, located within the STIM1 EF-hand and sterile α-motif domain, increased the release of Ca2+ from the endoplasmic reticulum in patient-derived fibroblasts and transfected HEK293T cells. This event was mediated by altered STIM1–sarco/endoplasmic reticulum calcium transport ATPase (SERCA) conformational change and enhanced SERCA pump activity leading to increased store-operated Ca2+ entry (SOCE). In pancreatic AR42J cells expressing the p.E152K variant, Ca2+ signaling perturbations correlated with defects in trypsin activation and secretion, and increased cytotoxicity after cholecystokinin stimulation. This article has an associated First Person interview with the first author of the paper
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

  • Noblejas-López, María del Mar
  • Nieto-Jiménez, Cristina
  • Burgos, Miguel
  • Gómez-Juárez, Mónica
  • Montero, Juan Carlos
  • Esparís-Ogando, Azucena
  • Pandiella, Atanasio
  • Galán-Moya, Eva María
  • Ocaña, Alberto
[Background] Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity of two novel BET-PROTACs, MZ1 and ARV-825, in TNBC, ovarian cancer and in a BET inhibitor resistant model., [Methods] OVCAR3, SKOV3, BT549, MDA-MB-231 cell lines and the JQ1 resistant cell line MDA-MB-231R were evaluated. MTTs, colony-forming assay, three-dimensional cultures in matrigel, flow cytometry, and western blots were performed to explore the anti-proliferative effect and biochemical mechanism of action of MZ1 and ARV-825. In vivo studies included BALB/c nu/nu mice engrafted with MDA-MB-231R cells., [Results] The BET-PROTACs MZ1 and ARV-825 efficiently downregulated the protein expression levels of the BET protein BRD4, in MDA-MB-231 and MDA-MB-231R. MZ1 and ARV-825 also showed an antiproliferative effect on sensitive and resistant cells. This effect was corroborated in other triple negative (BT549) and ovarian cancer (SKOV3, OVCAR3) cell lines. MZ1 provoked G2/M arrest in MDA-MB-231. In addition, a profound effect on caspase-dependent apoptosis was observed in both sensitive and resistant cells. No synergistic activity was observed when it was combined with docetaxel, cisplatin or olaparib. Finally, in vivo administration of MZ1 rescued tumor growth in a JQ1-resistant xenograft model, reducing the expression levels of BRD4., [Conclusions] Using both in vitro and in vivo approaches, we describe the profound activity of BET-PROTACs in parental and BETi-resistant TNBC models. This data provides options for further clinical development of these agents in TNBC., This work has been supported by Instituto de Salud Carlos III (PI16/01121), ACEPAIN; Diputación de Albacete, CIBERONC and CRIS Cancer Foundation (to A. Ocaña). Ministry of Economy and Competitiveness of Spain (BFU2015–71371-R and BFU2015–69874-r), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD12/0036/0003) and CIBERONC, the scientific foundation of the AECC and the CRIS Foundation (to A. Pandiella). The work carried out in our laboratories receive support from the European Community through the regional development funding program (FEDER). J.C. Montero is funded by the Instituto de Salud Carlos III through a Miguel Servet program (CPII17/00015) and receives research support from the same institution (PI15/00684 and PI18/00796). E.M. Galan-Moya is funded by the implementation research program of the UCLM (UCLM resolution date: 31/07/2014), with a contract for accessing the Spanish System of Science, Technology and Innovation-SECTI (co-funded by the European Commission/FSE funds). M. Burgos is funded by the Spanish Ministry for Science and Innovation, ref.: BFU2015–69874-R and Castilla-La Mancha support grant for Biomedicine and Health Science Research ref.: II-2018_11., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

  • Nieto-Jiménez, Cristina
  • Galán-Moya, Eva María
  • Corrales-Sánchez, Verónica
  • Noblejas-López, María del Mar
  • Burgos, Miguel
  • Domingo, Beatriz
  • Montero, Juan Carlos
  • Gómez-Juárez, Mónica
  • Picazo-Martinez, Maria Granada
  • Esparís-Ogando, Azucena
  • Pandiella, Atanasio
  • Ocaña, Alberto
The inhibition of bromo- and extraterminal domains (BET) has shown an anti-proliferative effect in triple negative breast cancer (TNBC). In this article we explore mechanisms of resistance to BET inhibitors (BETi) in TNBC, with the aim of identifying novel ways to overcome such resistance. Two cellular models of acquired resistance to the BET inhibitor JQ1 were generated using a pulsed treatment strategy. MTT, colony formation, and cytometry assays revealed that BETi-resistant cells were particularly sensitive to PLK1 inhibition. Targeting of the latter reduced cell proliferation, especially in resistant cultures. Quantitative PCR analysis of a panel of mitotic kinases uncovered an increased expression of AURKA, TTK, and PLK1, confirmed by Western blot. Only pharmacological inhibition of PLK1 showed anti-proliferative activity on resistant cells, provoking G2/M arrest, increasing expression levels of cyclin B, pH3 and phosphorylation of Bcl-2 proteins, changes that were accompanied by induction of caspase-dependent apoptosis. JQ1-resistant cells orthotopically xenografted into the mammary fat pad of mice led to tumours that retained JQ1-resistance. Administration of the PLK1 inhibitor volasertib resulted in tumour regression. These findings open avenues to explore the future use of PLK1 inhibitors in the clinical setting of BETi-resistant patients., This work has been supported by Instituto de Salud Carlos III (PI16/01121 and PI19/00808), ACEPAIN; Diputación de Albacete, CIBERONC and CRIS Cancer Foundation (to A. Ocaña). Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R), the Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program (RD12/0036/0003) and CIBERONC, the scientific foundation of the AECC and the CRIS Foundation (to A. Pandiella). The work carried out in our laboratories receive support from the European Community through the regional development funding program (FEDER). J.C. Montero is a recipient of a Miguel Servet fellowship program (CP12/03073 and CPII17/00015) and receives research support from the ISCIII (grants PI15/00684 and PI18/00796). E.M. Galan-Moya is funded by the implementation research program of the UCLM (UCLM resolution date: July 31, 2014), with a contract for accessing the Spanish System of Science, Technology and Innovation-SECTI (co-funded by the European Commission/FSE funds) and Council of Communities of Castilla-La Mancha (JCCM) (SBPLY/19/180501/000173). M. Burgos is funded by the Spanish Ministry for Science and Innovation, ref: BFU2015-69874-R and Castilla-La Mancha support grant for Biomedicine and Health Science Research ref: II-2018_11., Peer reviewed